AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
Ikena, Senti and others look to clinical presentations at AACR.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
